<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895463</url>
  </required_header>
  <id_info>
    <org_study_id>A-PL-52030-380</org_study_id>
    <secondary_id>2018-002149-13</secondary_id>
    <nct_id>NCT03895463</nct_id>
  </id_info>
  <brief_title>Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice</brief_title>
  <acronym>NETways</acronym>
  <official_title>Prospective Noninterventional Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Tumours (GEP-NETs) in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to assess the Progression-Free Survival (PFS) at 12 months of
      Lanreotide Autogel 120 mg use when administered as part of routine GEP-NET treatment and to
      follow patient treatment pathways, identify prognostic factors of PFS, evaluate patient's
      QoL, and patient's and clinician's satisfaction with treatment in routine long-term care
      setting. The study will provide real-world evidence on the use of Lanreotide Autogel 120 mg
      and will provide information on topics such as optimization of product usage and
      identification of best practices and will provide evidence on product effectiveness in a
      realistic setting.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Reassessment of study feasibility
  </why_stopped>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">March 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 26, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>To estimate the rate according to investigator assessment (radiological progression; based on Response Evaluation Criteria In Solid Tumours version 1.0 [RECIST 1.0])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median PFS</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour origin</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour grade</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>24 months</time_frame>
    <description>To describe the change in Quality of Life (QoL) as assessed by European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire for gastrointestinal neuroendocrine tumours (QLQ-GINET21 questionnaires). Where the patient assess experienced symptoms or problems using the scale from 1 to 4. Where 1 represents &quot;not at all&quot; and 4 &quot;very much&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>24 months</time_frame>
    <description>To estimate the Disease Control Rate (DCR), as assessed by investigator (proportion of subjects with a best overall response of Partial Response [PR], Complete Response [CR] or Stable Disease [SD]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chromogranin A (CgA) level</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate patients' satisfaction using abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). It assesses key dimensions of treatment satisfaction: Effectiveness, Convenience and Global Satisfaction. The effectiveness scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the convenience scored as 1 (extremely difficult) to 7 (extremely easy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 5-hydroxyindoleaceticacid (5-HIAA) levels</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects with GEP-NETs eligible for treatment with Lanreotide Autogel 120 mg or
        currently being treated with Lanreotide Autogel 120 mg every 28 days for a period of up to
        5 months. Subjects will receive treatment as prescribed by the physician and in accordance
        with the current Summary of Product Characteristics (SmPC).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functioning or non-functioning histopathologically confirmed, locally advanced or
             metastatic (grade 1 or grade 2 according to the World Health Organisation (WHO) 2017
             classification and European Neuroendocrine Tumour Society (ENETS) grading system)
             GEP-NET G1,G2 (Ki67≤10%, based on recent Ki67).

          -  Measurable disease, as defined by RECIST 1.0, on a CT scan/MRI obtained up to 6 weeks
             prior to initiation of treatment with Lanreotide Autogel 120 mg.

          -  Subject eligible for treatment with Lanreotide Autogel 120 mg or subject currently
             being treated with Lanreotide Autogel 120 mg administered every 28 days for a period
             no longer than 5 months prior to inclusion

          -  Treatment with Lanreotide Autogel 120 mg alone, according to local Summary of Product
             Characteristics (SmPC).

        Exclusion Criteria:

          -  Lanreotide Autogel treatment for more than 5 months prior to inclusion into the study

          -  Concomitant anti-proliferative medication/therapies for GEP NET at initiation of
             Lanreotide Autogel treatment (e.g. Peptide Receptor Radionuclide Therapy (PRRT),
             cytotoxic chemotherapy, targeted therapy everolimus, sunitinib, interferon,
             loperamide).

          -  Has been treated with PRRT, chemotherapy, everolimus, sunitinib or interferon within 3
             months prior to initiation of Lanreotide Autogel treatment

          -  Parallel participation in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <zip>44102</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40514</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Onkologii</name>
      <address>
        <city>Kielce</city>
        <zip>25734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>31501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>60355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego im. prof. Tadeusza Sokołowskiego</name>
      <address>
        <city>Szczecin</city>
        <zip>71252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie</name>
      <address>
        <city>Warsaw</city>
        <zip>02034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego, Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <zip>02097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnośląskie Centrum Onkologii we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>53413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <zip>92213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

